Pharmaceutical

Elahere secures full approval from FDA for types of ovarian cancer

The FDA granted accelerated approval for the drug back in November 2022, and granted priority review in December 2023.

Mar 26, 2024 - 00:00
Elahere secures full approval from FDA for types of ovarian cancer
The FDA granted accelerated approval for the drug back in November 2022, and granted priority review in December 2023.
Read the original article

Tags:

Previous Article

Novo shells out $1.1bn to buy Cardior to expand cardiovascular pipeline

Next Article

CRISPR-based assay could revolutionise diagnosis of NTM infections

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AbbVie wins UK NICE endorsement for subcutaneous Tepkinly in DLBCL

AbbVie wins UK NICE endorsement for subcutaneous Tepkin...

Feb 2, 2024

Most drugmakers have so far ignored looming FTC deadline to withdraw or amend wayward patents

Most drugmakers have so far ignored looming FTC deadlin...

Dec 7, 2023

STAT+: Early data are promising for autoimmune disease drug from Roivant Sciences’ Immunovant

STAT+: Early data are promising for autoimmune disease ...

Sep 26, 2023